<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Soul of Biotech &#187; pharmacogenomics</title>
	<atom:link href="http://www.thesoulofbiotech.com/category/pharmacogenomics/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thesoulofbiotech.com</link>
	<description>Laughter is the best medicine -- but let's cure cancer anyway.</description>
	<lastBuildDate>Fri, 10 Jul 2009 18:46:53 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=abc</generator>
		<item>
		<title>My BIL &#8217;09 talk video is online!</title>
		<link>http://www.thesoulofbiotech.com/2009/03/10/my-bil-09-talk-video-is-online/</link>
		<comments>http://www.thesoulofbiotech.com/2009/03/10/my-bil-09-talk-video-is-online/#comments</comments>
		<pubDate>Wed, 11 Mar 2009 06:39:17 +0000</pubDate>
		<dc:creator>Jonathan</dc:creator>
				<category><![CDATA[bil]]></category>
		<category><![CDATA[conference]]></category>
		<category><![CDATA[pharmacogenomics]]></category>
		<category><![CDATA[regulations]]></category>

		<guid isPermaLink="false">http://www.thesoulofbiotech.com/?p=131</guid>
		<description><![CDATA[The Promise and the Peril of Personalized Medicine from Jeriaska on Vimeo. Many thanks to Drew Reynolds for taping this and editing together this abbreviated version. The uncut talk was about ten minutes long &#8212; I started out explaining what treatment-response biomarkers are, and how they can improve patient outcomes and save money for payors.]]></description>
		<wfw:commentRss>http://www.thesoulofbiotech.com/2009/03/10/my-bil-09-talk-video-is-online/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
		</item>
		<item>
		<title>EEOC invites comment on GINA</title>
		<link>http://www.thesoulofbiotech.com/2009/02/28/eeoc-invites-comment-on-gina/</link>
		<comments>http://www.thesoulofbiotech.com/2009/02/28/eeoc-invites-comment-on-gina/#comments</comments>
		<pubDate>Sat, 28 Feb 2009 18:22:31 +0000</pubDate>
		<dc:creator>Jonathan</dc:creator>
				<category><![CDATA[genetics]]></category>
		<category><![CDATA[pharmacogenomics]]></category>
		<category><![CDATA[regulations]]></category>

		<guid isPermaLink="false">http://www.thesoulofbiotech.com/?p=125</guid>
		<description><![CDATA[The EEOC has invited the public to comment on the Genetic Information Nondiscrimination Act (GINA). GINA was passed in the spring of 2008 as a way to bar employers from discriminating against employees on the basis of genetic information. GINA also prevents healthcare insurers from discriminating based on genetic information. GINA is an important step [...]]]></description>
		<wfw:commentRss>http://www.thesoulofbiotech.com/2009/02/28/eeoc-invites-comment-on-gina/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Notes from the 2009 Harvard Business School Healthcare Conference (Part 2)</title>
		<link>http://www.thesoulofbiotech.com/2009/01/22/notes-from-the-2009-harvard-business-school-healthcare-conference-part-2/</link>
		<comments>http://www.thesoulofbiotech.com/2009/01/22/notes-from-the-2009-harvard-business-school-healthcare-conference-part-2/#comments</comments>
		<pubDate>Thu, 22 Jan 2009 20:33:51 +0000</pubDate>
		<dc:creator>Jonathan</dc:creator>
				<category><![CDATA[conference]]></category>
		<category><![CDATA[enbrel]]></category>
		<category><![CDATA[hbs]]></category>
		<category><![CDATA[pharmacogenomics]]></category>

		<guid isPermaLink="false">http://www.thesoulofbiotech.com/?p=109</guid>
		<description><![CDATA[The next session I attended was the personalized medicine panel, which was new this year. The panelists spoke to a standing-room-only crowd in an HBS lecture hall. The panelists briefly explained what personalized medicine was, and emphasized its importance as technology began to deliver whole genome sequences for less and less money. The first human [...]]]></description>
		<wfw:commentRss>http://www.thesoulofbiotech.com/2009/01/22/notes-from-the-2009-harvard-business-school-healthcare-conference-part-2/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Meet Danny Halperin</title>
		<link>http://www.thesoulofbiotech.com/2007/07/29/meet-danny-halperin/</link>
		<comments>http://www.thesoulofbiotech.com/2007/07/29/meet-danny-halperin/#comments</comments>
		<pubDate>Mon, 30 Jul 2007 01:39:50 +0000</pubDate>
		<dc:creator>Jonathan</dc:creator>
				<category><![CDATA[academia]]></category>
		<category><![CDATA[amgen]]></category>
		<category><![CDATA[interview]]></category>
		<category><![CDATA[pharmacogenomics]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://www.thesoulofbiotech.com/2007/07/29/meet-danny-halperin/</guid>
		<description><![CDATA[Danny Halperin is a second-year graduate student in Molecular &#038; Cellular Pathology at the University of California at Los Angeles, working in the laboratory of Dr. Peter Tontonoz. Before attending UCLA, Danny spent four years at Amgen in Clinical Immunology supporting pre-clinical and clinical development of biologics. Danny and I sat down over Thai food [...]]]></description>
		<wfw:commentRss>http://www.thesoulofbiotech.com/2007/07/29/meet-danny-halperin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What does genetic screening mean for the drug industry?</title>
		<link>http://www.thesoulofbiotech.com/2007/06/23/what-does-genetic-screening-mean-for-the-drug-industry/</link>
		<comments>http://www.thesoulofbiotech.com/2007/06/23/what-does-genetic-screening-mean-for-the-drug-industry/#comments</comments>
		<pubDate>Sat, 23 Jun 2007 07:51:54 +0000</pubDate>
		<dc:creator>Jonathan</dc:creator>
				<category><![CDATA[marketing]]></category>
		<category><![CDATA[nytimes]]></category>
		<category><![CDATA[pharmacogenomics]]></category>
		<category><![CDATA[sales]]></category>

		<guid isPermaLink="false">http://www.thesoulofbiotech.com/2007/06/23/what-does-genetic-screening-mean-for-the-drug-industry/</guid>
		<description><![CDATA[My friend Lexi sent me a link to a NYT article that discusses personalized medicine (also known as pharmacogenomics), which is an area of great interest to me. It&#8217;s what I focused on in my master&#8217;s work, and it&#8217;s an area that, given the right opportunity, I intend to start a biotech in one day. [...]]]></description>
		<wfw:commentRss>http://www.thesoulofbiotech.com/2007/06/23/what-does-genetic-screening-mean-for-the-drug-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.583 seconds -->
